22840-1685 : Gliocladium Viride 20000 [Pnu]/Ml Intradermal; Percutaneous; Subcutaneous Solution
NDC: | 22840-1685 |
Labeler: | Greer Laboratories, Inc. |
Product Type: | Non-standardized Allergenic |
Drug Name: | Gliocladium Viride |
Dosage Form: | Intradermal; Percutaneous; Subcutaneous Solution |
Application #: | BLA101833 |
Rev. Date: |
NDC Package Codes:
- 22840-1685-2: 10 ML IN 1 VIAL, MULTI‑DOSE (22840‑1685‑2)
- 22840-1685-4: 50 ML IN 1 VIAL, MULTI‑DOSE (22840‑1685‑4)
Active Ingredients:
- Gliocladium Viride
Dosage Strength:
- 20000 [PNU]/mL
Pharmaceutical Classes:
- Non-Standardized Fungal Allergenic Extract [EPC]
- Increased Histamine Release [PE]
- Cell-mediated Immunity [PE]
- Increased IgG Production [PE]
- Fungal Proteins [CS]
- Allergens [CS]
Related Products:
Based on records with the same trade name.- 22840-1681 Gliocladium Viride .1 g/ml Intradermal; Percutaneous; Subcutaneous Solution by Greer Laboratories, Inc.
- 22840-1682 Gliocladium Viride .05 g/ml Intradermal; Percutaneous; Subcutaneous Solution by Greer Laboratories, Inc.
- 22840-1683 Gliocladium Viride .001 g/ml Intradermal; Percutaneous; Subcutaneous Solution by Greer Laboratories, Inc.
- 22840-1684 Gliocladium Viride 1000 [Pnu]/Ml Intradermal; Percutaneous; Subcutaneous Solution by Greer Laboratories, Inc.
- 22840-1686 Gliocladium Viride 40000 [Pnu]/Ml Intradermal; Percutaneous; Subcutaneous Solution by Greer Laboratories, Inc.
- 22840-5621 Gliocladium Viride .05 g/ml Intradermal; Percutaneous; Subcutaneous Solution by Greer Laboratories, Inc.
NDC QR Code
Scan the QR code below to easily reference this data in the future:< Prev: 22840-1684Next: 22840-1686 >
Note: The RxChat NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.